Evaluation of malignancies and F18-FDG PET/CT imaging of patients living with HIV/AIDS in a university hospital
Mehmet Çabalak,Hasan İkbal Atılgan.
Abstract
Aim:Human immunodeficiency virus (HIV) can cause tumoral changes in immune cells and lead to the development of AIDS-defining malignancies. As malignancies in HIV-infected individuals tend to be quite aggressive with a worse prognosis, making a definitive and early decision about HIV-related malignancies is very important.Therefore, the aim of this study was to examine HIV-related malignancies in HIV-positive patients and evaluate F-18 FDG PET/CT results.
Materials and Methods: This single-centre, retrospective study was conducted on adult patients with HIV infection at a university hospital between January 2018 and December 2022. The demographic data, medication use, viral loads, and F-18 FDG PET/CT results of the patients were accessed retrospectively from the automated hospital records system and patient files. F18-FDG PET/CT images of patients were evaluated for those with suspicion of cancer and staging of cancer.
Results: The study included 254 patients (median age: 33±13.8 years, male sex: 81.9%). Malignancy was diagnosed in 3.1% (8/254) of HIV-positive patients. Non-Hodgkin Lymphoma and Kaposi Sarcoma were the most common cancers. F-18 FDG PET/CT was performed in 3.5% (9/254) of patients, of which 2.76% (7/254) had findings suggestive of malignancy. As a result of the biopsy, malignancy was detected in five of these patients, and HIV-related lymphadenopathy was detected in two. In two patients, there were no F-18 FDGPET/CT imaging findings suggestive of malignancy.
Conclusion: F-18 FDG PET/CT can be used in in the evaluation of HIV-infected patients with suspected malignancy.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
